Navigation Links
Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia
Date:9/10/2012

LONDON and MOSCOW, September 11, 2012 /PRNewswire/ --

Subcutaneous blood factors expected to revolutionise the treatment paradigm of haemophiliac patients worldwide

Pro Bono Bio Group plc ("PBB"), the international healthcare group, announces the successful conclusion of a series of pre-clinical trials in haemophiliac subjects conducted with the world's first long acting blood Factors VIIa, VIII and IX capable of subcutaneous administration. The results of these trials are of great importance as these novel long-acting, subcutaneous blood factors are expected to revolutionise the treatment paradigm for haemophilia sufferers worldwide. The availability of PBB's subcutaneous blood factors would make self-administration by patients at home much easier leading to a significant improvement in treatment compliance and reduction in healthcare system costs by avoiding the need for regular IV infusions.

Key findings from the 8 trials with 6 products conducted at the University of Alabama were:

  • PBB's current subcutaneous form of FVIIa achieved up to 3 days of haemostatic cover providing the prospect of sustained prophylactic treatment for haemophilia A patients who suffer an immune response to FVIII meaning that FVIII is no longer a viable therapy for them.
  • PBB's current intravenous form of Factor VIIa achieved a 12x extension of haemostasis over current commercially available products. This means it could offer significant advantages in trauma applications in hospitals where haemostatic cover can be maintained for the duration of long operations and post-operation, without the current need for multiple administrations and related complications.
  • PBB's subcutaneous form of Factor VIII for haemophilia A achieved a circulating dose level of 20% of the intravenous version and also maintained haemostasis for 72 hours, meaning that it is already suitable for twice-weekly dosing a
    '/>"/>

SOURCE Pro Bono Bio
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) has announced ... "Neuroprotection - Drugs, Markets and Companies" to ... role of neuroprotection in acute disorders such as ... well as in chronic diseases such as neurodegenerative ... damage to neural tissues are similar in all ...
(Date:5/28/2015)... 2015 DryLet, LLC a biotechnology ... such as animal waste reduction, bioremediation, wastewater treatment, ... wastewater treatment plants and restaurant kitchen settings, announced ... Expo, June 3-5 in Des Moines, Iowa. , ... Wall Street Journal article because of its industry-leading ...
(Date:5/28/2015)... , May 28, 2015 Biscayne ... anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology ... the 2015 ASCO Annual Meeting. The data show that ... Biscayne,s anti-cancer GHRH blockers, is present on many primary ... findings suggest that GHRH antagonists could have broad anti-cancer ...
(Date:5/28/2015)... Glenn Keet, CEO of Clinovo ... EMR/EHR Clinical Data Integration with EDC Systems ” at ... DC on June 14th-18th. , During the presentation, Glenn ... with EDC, and will examine the value of patient ... electronic health records/electronic medical records integration. , The ...
Breaking Biology Technology:Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3DryLet to Showcase Patented ManureMagic™ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed ... its U.K. clinical trial to evaluate the,anti-tumour ... with docetaxel (Taxotere(R)) in patients with advanced ... The,principal investigator is Professor Hardev Pandha of ...
... (Amex:,SVA), a vaccine-focused biotech company in China, announced today ... on Thursday, September 4,2008 at 9:00 a.m. Beijing Time. ... Xi Road, Haidian District, Beijing, PRC and at No. ... as of August 1,2008 will be eligible to vote ...
... today announced that the first patient has received an ... Company,s first oncology product, MM-121, a,fully human monoclonal antibody ... ErbB3 receptor., ErbB3 is a receptor in the ... cancer signaling. With the initiation of the Phase 1 ...
Cached Biology Technology:Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial 2Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial 3Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders 2Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist 2Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist 3
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/19/2015)... NEW YORK , May 19, 2015  Technology ... resources both internally and in the cloud. Passwords and ... the use of OTP and standards-based specifications such as ... that the outmoded use of passwords presents for BYOD, ... needs a unified biometric identity protocol. ...
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... of the "Fingerprint Sensors Market in Smart Mobile ... This report believes that 2014 was a watershed year ... Apple,s introduction of ,Apple Pay,. Apple gave fingerprint sensors ... mobile payment service. Fingerprint sensors are a must-have feature ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
... emotional expression that is innate in human beings. This means ... phenomenon. However, the fear of being laughed at causes some ... as gelotophobia, a disorder that affects people in all cultures ... and another who suffers from gelotophobia? One of the aims ...
... DIEGO, Oct. 13 CareFusion Corporation (NYSE: CFN ), ... launch of the EnVe(TM) ventilator - a high-performance critical care ... the EnVe ventilator is 70-80 pounds lighter than other intensive ... technology to help hospitals increase the quality of patient care ...
... useful in electronics applications, Kansas State University engineers made ... Vikas Berry is a K-State assistant professor of chemical ... a single atom thick and discovered just five years ... its electronics properties -- Berry and Kabeer Jasuja, a ...
Cached Biology News:Fear of being laughed at crosses cultural boundaries 2Fear of being laughed at crosses cultural boundaries 3Fear of being laughed at crosses cultural boundaries 4CareFusion Launches EnVe(TM) Ventilator: 10-Pound High-Performance Critical Care Ventilator 2CareFusion Launches EnVe(TM) Ventilator: 10-Pound High-Performance Critical Care Ventilator 324-carat gold 'snowflakes' improve graphene's electrical properties 2
... Source: Tritirachium album Description: Proteinase ... used in a wide range of applications purified ... bonds mainly following the carboxyl group of N-substituted ... and is classified as a serine protease. Proteinase ...
... high throughput, water bath thermal cycler capable of ... This equates to 9,216 reactions per run when ... transfers a basket of plates between three water ... considerably faster than those of peltier block cyclers. ...
... Dideoxycytidine is a cytidine analog that has been ... Immunogen: Chemical / Small Molecule ... specificity of the ddC antiserum was determined by ... to moles of ddC analog at the 50% ...
... The Jouan MSC series of Class ... working conditions and certification to the ... regulation ensures that the cabinets cannot ... conditions. Natural lighting, low noise and ...
Biology Products: